Literature DB >> 8938150

Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines.

M Hala1, B L Hartmann, G Böck, S Geley, R Kofler.   

Abstract

The application of glucocorticoids (GC3) in human leukemia is based on apoptosis induction but is often hampered by GC resistance. To delineate resistance mechanisms, we examined 5 GC-resistant leukemic cell lines, termed CEM-C7.R1-R5, isolated from the GC-sensitive human acute-T-cell-leukemic line, CCRF-CEM-C7, by selection in GC-containing medium. GC resistance was ascertained by analyzing cell-cycle progression, proliferation, and apoptosis. Radioreceptor assays revealed absence of ligand-binding activity in all clones, suggesting that defects in GC-receptor(GR) expression cause GC resistance. Analyses of the GR gene revealed that all but one (CEM-C7.R5) of the clones were heterozygous for the previously described L753F mutation. CEM-C7.R5 was either hemi- or homozygous for the L753F mutation and, hence, lacked a functional GR. Sequencing of the allele not carrying the L753F mutation of the other GC-resistant sub-lines revealed additional mutations in the GR gene in 3 cases: CEM-C7.R1 and R2 had a base-pair deletion in exon 9 (deltaT740) that resulted in a reading-frame shift and a pre-terminal in-frame stop. Translation of this mutant mRNA would produce a protein lacking 32 amino acids and expressing 4 altered residues at its new C terminus. CEM-C7.R3 harbored a non-sense mutation (Q710X) in exon 8, and its mRNA would be translated into a protein lacking 67 residues. Only CEM-C7.R4 cells were devoid of mutations in the coding region of the L753F negative allele. These data suggest that, in the CCRF-CEM acute-lymphatic-leukemia model, mutations in the GR-gene coding region represent one, but not the only, cause of GC resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938150     DOI: 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models.

Authors:  Rocco Sciarrillo; Anna Wojtuszkiewicz; Irsan E Kooi; Valentina E Gómez; Ugo Boggi; Gerrit Jansen; Gert-Jan Kaspers; Jacqueline Cloos; Elisa Giovannetti
Journal:  J Vis Exp       Date:  2016-12-09       Impact factor: 1.355

2.  Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.

Authors:  Sang-Woo Kim; Deepak Rai; Ricardo C T Aguiar
Journal:  Clin Cancer Res       Date:  2011-07-08       Impact factor: 12.531

3.  Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.

Authors:  Anica M Wandler; Benjamin J Huang; Jeffrey W Craig; Kathryn Hayes; Hannah Yan; Lauren K Meyer; Alessandro Scacchetti; Gabriela Monsalve; Monique Dail; Qing Li; Jasmine C Wong; Olga Weinberg; Robert P Hasserjian; Scott C Kogan; Philip Jonsson; Keith Yamamoto; Deepak Sampath; Joy Nakitandwe; James R Downing; Jinghui Zhang; Jon C Aster; Barry S Taylor; Kevin Shannon
Journal:  Leukemia       Date:  2020-02-17       Impact factor: 11.528

4.  Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.

Authors:  Francis Robert; William Roman; Alexandre Bramoullé; Christof Fellmann; Anne Roulston; Chaim Shustik; John A Porco; Gordon C Shore; Michael Sebag; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

5.  The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.

Authors:  Nicolas Pottier; Wenjian Yang; Mahfoud Assem; John C Panetta; Deqing Pei; Steven W Paugh; Cheng Cheng; Monique L Den Boer; Mary V Relling; Rob Pieters; William E Evans; Meyling H Cheok
Journal:  J Natl Cancer Inst       Date:  2008-12-09       Impact factor: 13.506

6.  Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.

Authors:  Almut Bokemeyer; Cornelia Eckert; Franziska Meyr; Gabriele Koerner; Arend von Stackelberg; Reinhard Ullmann; Seval Türkmen; Günter Henze; Karl Seeger
Journal:  Haematologica       Date:  2013-11-15       Impact factor: 9.941

Review 7.  Molecular mechanisms regulating glucocorticoid sensitivity and resistance.

Authors:  Katherine L Gross; Nick Z Lu; John A Cidlowski
Journal:  Mol Cell Endocrinol       Date:  2008-10-19       Impact factor: 4.102

8.  Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.

Authors:  T Melarangi; J Zhuang; K Lin; N Rockliffe; A G Bosanquet; M Oates; J R Slupsky; A R Pettitt
Journal:  Cell Death Dis       Date:  2012-08-16       Impact factor: 8.469

9.  Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.

Authors:  Justine E Roderick; Kayleigh M Gallagher; Leonard C Murphy; Kevin W O'Connor; Katherine Tang; Boyao Zhang; Michael A Brehm; Dale L Greiner; Jun Yu; Lihua Julie Zhu; Michael R Green; Michelle A Kelliher
Journal:  Blood       Date:  2021-01-28       Impact factor: 25.476

10.  Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition.

Authors:  Lindsay Nicholson; Caroline A Evans; Elizabeth Matheson; Lynne Minto; Christopher Keilty; Maryna Sanichar; Marian Case; Claire Schwab; Daniel Williamson; Johannes Rainer; Christine J Harrison; Reinhard Kofler; Andrew G Hall; Christopher P F Redfern; Anthony D Whetton; Julie A E Irving
Journal:  Br J Haematol       Date:  2015-08-27       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.